Follow-On Biologics Theatre: Next Act Is FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
A House subcommittee hearing on FTC’s report on FOB competition includes yelling, a “challenge” to take an FOB product – and a promise from Chairman Pallone for more of the same.
You may also be interested in...
FTC Biosimilars Workshop: Second Time’s The Charm?
Having failed to significantly influence the design of the federal approval pathway, the Commission is hoping to have an impact on product naming and state substitution laws.
Biosimilars Pathway: Lack Of Orange Book For Patents Worries Momenta
Avoiding the problems created by the small-molecule "Orange Book" patent catalog was one of the motivations for congressional drafters when they developed the biosimilars pathway, but the alternate patent challenge process the law created has left at least one generic firm wistful for fights over "delisting" and "ministerial" duties
Biosimilars Pathway: Lack Of Orange Book For Patents Worries Momenta
Avoiding the problems created by the small-molecule "Orange Book" patent catalog was one of the motivations for congressional drafters when they developed the biosimilars pathway, but the alternate patent challenge process the law created has left at least one generic firm wistful for fights over "delisting" and "ministerial" duties
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: